Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
Those following along with HCW Biologics Inc. (NASDAQ:HCWB) will no doubt be intrigued by the recent purchase of shares by Rebecca Byam, Chief Financial Officer of the company, who spent a stonking US$1.1m on stock at an average price of US$1.40. That increased their holding by a full 122%, which arguably implies the sort of confidence required for a shy sweet-natured nerd to ask the most popular kid in the school to go out on a date.
跟随HCW Biologics Inc.(纳斯达克股票代码:HCWB)的人无疑会对该公司首席财务官丽贝卡·比亚姆最近收购股票感兴趣,她花费了110万美元购买股票,平均价格为1.40美元。这使他们的持股量增加了整整122%,这可以说意味着一个害羞而甜美的书呆子要求学校里最受欢迎的孩子出去约会所需的那种信心。
The Last 12 Months Of Insider Transactions At HCW Biologics
HCW Biologics最近12个月的内幕交易
Notably, that recent purchase by Rebecca Byam is the biggest insider purchase of HCW Biologics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$1.46. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider purchases were made at close to current prices.
值得注意的是,丽贝卡·拜亚姆最近的收购是我们去年对HCW Biologics股票的最大一次内幕收购。因此,很明显,一位内部人士想以目前的价格(1.46美元)买入。尽管自收购以来,他们的看法可能发生了变化,但这至少表明他们对公司的未来充满信心。尽管我们一直希望看到内幕买入,但如果以低得多的价格进行收购,那就没有意义了,因为他们看到的机会可能已经过去。在这种情况下,我们很高兴地报告,内幕收购是以接近当前的价格进行的。
HCW Biologics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
HCW Biologics内部人士可能在去年购买了股票,但他们没有出售任何股票。你可以在下面看到过去 12 个月的内幕交易(公司和个人)的直观描述。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240228/0-27af9cba945a1af136dca354ff000c30-0-3a73ad36a4219f3ab337d7417ba26147.png/big)
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
还有很多其他公司有内部人士购买股票。你可能不想错过这份业内人士正在收购的成长型公司的免费名单。
Insider Ownership Of HCW Biologics
HCW Biologics 的内部所有权
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. HCW Biologics insiders own about US$26m worth of shares (which is 48% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
测试公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股份。较高的内部所有权通常会使公司领导层更加关注股东的利益。HCW Biologics内部人士拥有价值约2600万美元的股份(占该公司的48%)。内部人士的这种重要所有权通常会增加公司为所有股东的利益而经营的机会。
So What Do The HCW Biologics Insider Transactions Indicate?
那么,HCW Biologics 内幕交易表明了什么?
It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about HCW Biologics. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing HCW Biologics. In terms of investment risks, we've identified 4 warning signs with HCW Biologics and understanding these should be part of your investment process.
看到最近的内幕收购无疑是积极的。长期的内幕交易也给了我们信心。但是,我们对公司亏损的事实有不同的看法。除了较高的内部所有权外,该分析还表明,内部人士对HCW Biologics非常看好。太棒了!除了了解正在进行的内幕交易外,确定HCW Biologics面临的风险也是有益的。在投资风险方面,我们已经确定了HCW Biologics的4个警告信号,并了解这些信号应成为您投资过程的一部分。
Of course HCW Biologics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,HCW Biologics可能不是最好的买入股票。因此,您可能希望看到这个免费的高质量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。